-
Purpose3rd generation lentiviral expression of constitutively active Stat3
-
Depositing Lab
-
Publication
-
Sequence Information
Ordering
Item | Catalog # | Description | Quantity | Price (USD) | |
---|---|---|---|---|---|
Plasmid | 24983 | Standard format: Plasmid sent in bacteria as agar stab | 1 | $85 |
Backbone
-
Vector backbonecFUGW
- Backbone size w/o insert (bp) 11500
-
Vector typeMammalian Expression, Lentiviral
-
Selectable markersEGFP
Growth in Bacteria
-
Bacterial Resistance(s)Ampicillin, 100 μg/mL
-
Growth Temperature37°C
-
Growth Strain(s)Stbl3
-
Copy numberHigh Copy
Gene/Insert
-
Gene/Insert nameSTAT3
-
SpeciesH. sapiens (human)
-
Insert Size (bp)2314
-
MutationA662C, N664C (constitutively active)
-
GenBank IDNM_139276.2
-
Entrez GeneSTAT3 (a.k.a. ADMIO, ADMIO1, APRF, HIES)
-
Tag
/ Fusion Protein
- FLAG (C terminal on insert)
Cloning Information
- Cloning method Restriction Enzyme
- 5′ cloning site PacI (destroyed during cloning)
- 3′ cloning site PacI (destroyed during cloning)
- 5′ sequencing primer EF1a-forward
- 3′ sequencing primer hUBCpro-R (Common Sequencing Primers)
Resource Information
-
Articles Citing this Plasmid
Terms and Licenses
-
Academic/Nonprofit Terms
-
Industry Terms
- Not Available to Industry
Trademarks:
- Zeocin® is an InvivoGen trademark.
Depositor Comments
A V667L mutation is present but not known to affect function.
Expression of EGFP is driven by the human ubiquitin promoter. See Addgene plasmid 14883: FUGW for more information on the empty vector.
These plasmids were created by your colleagues. Please acknowledge the Principal Investigator, cite the article in which the plasmids were described, and include Addgene in the Materials and Methods of your future publications.
-
For your Materials & Methods section:
EF.STAT3C.Ubc.GFP was a gift from Linzhao Cheng (Addgene plasmid # 24983 ; http://n2t.net/addgene:24983 ; RRID:Addgene_24983) -
For your References section:
The high-mobility group A1a/signal transducer and activator of transcription-3 axis: an achilles heel for hematopoietic malignancies?. Hillion J, Dhara S, Sumter TF, Mukherjee M, Di Cello F, Belton A, Turkson J, Jaganathan S, Cheng L, Ye Z, Jove R, Aplan P, Lin YW, Wertzler K, Reeves R, Elbahlouh O, Kowalski J, Bhattacharya R, Resar LM.. Cancer Research 68, 10121, December 2008. 10.1158/0008-5472.CAN-08-2121 PubMed 19074878